Samsung Biologics Partners with European Pharmaceutical Firm for Significant Manufacturing Agreement
This week, Samsung Biologics, recognized as a leading contract development and manufacturing organization (CDMO), announced a significant collaboration with an undisclosed pharmaceutical company from Europe. This arrangement comprises multiple manufacturing contracts exceeding 8 million, with services slated to continue through December 2031.
John Rim, the President and CEO of Samsung Biologics, stated, “We are thrilled to enhance our partnership with the European pharmaceutical firm as we collectively strive to deliver superior biopharmaceuticals to those in need.”
He added, “As we broaden our strategic collaborations worldwide, our ongoing investments in capabilities and manufacturing technologies are crucial. Our aim is to offer the highest quality services throughout all stages and to strengthen our trusted alliances.”
This announcement is part of a series of contracts that Samsung Biologics has secured in recent times across the U.S., Asia, and Europe, raising the total contract value for the company to over billion.
In October 2024, for instance, Samsung Biologics executed a notable manufacturing agreement valued at .24 billion with a pharmaceutical company based in Asia.
The firm is also gearing up to incorporate antibody-drug conjugate (ADC) services into its offerings by the end of 2024, planning to launch a specialized manufacturing facility soon. In February 2024, Samsung Biologics entered into a partnership with LegoChem Biosciences, a South Korean biotech company, to enhance the production of LegoChem’s ADC candidate targeting solid tumors.
Samsung Biologics is on track to inaugurate Plant 5, the inaugural facility of its second Bio Campus, by April 2025. Spanning an area of 96,000 m2, Plant 5 will have a capacity of 180,000 liters. The second Bio Campus will be fully operational next year, featuring large-scale manufacturing facilities and an open innovation center. This project, which commenced with land acquisition of 360,000 m2 in July 2022, has an estimated value of nearly .4 billion.
Rim commented on the situation, stating, “Considering the rising demand for outsourced biopharmaceutical manufacturing, we are proactively investing in line with our growth strategy to reinforce our position as a premier CDMO.” He emphasized, “The upcoming facility will allow us to deliver increased innovation and services to our customers, enhancing speed to market and flexibility.”